治病良藥還是癌症元兇？馬兜鈴酸「導致肝癌」事件調查 美國《科學─轉化醫學》雜誌10月中旬發表一篇封面論文，題為《臺灣及更廣亞洲地區的 肝癌與馬兜鈴酸及其衍生物廣泛相關》，雜誌編輯以「一種草藥的黑暗面」為題推薦了這 篇論文。而這篇論文的結論是：馬兜鈴酸與肝癌之間存在「決定性關聯」。 基於對全世界共計1400多個肝癌樣本的分析，論文指出，含馬兜鈴酸的草藥在亞洲尤其臺 灣被廣泛使用，但並沒有直接說馬兜鈴酸是當地肝癌高發的原因。 針對這篇論文的內容，國家食品藥品監督管理總局新聞發言人回應稱，根據流行病學大樣 本、大資料分析，我國肝癌患者主要由乙肝病毒感染引起。是否與馬兜鈴酸有直接關係， 尚無直接有力的資料支撐。 食藥監總局新聞發言人指出，雖然馬兜鈴酸與肝癌的直接相關性尚無直接有力資料支撐， 但馬兜鈴酸具有明顯腎毒性，可造成腎小管功能受損，甚至存在引發腎癌的風險 http://www.storm.mg/article/353822 The dark side of an herbal medicine Aristolochic acid, an herbal compound found in many traditional medicines, had been previously linked to kidney failure, as well as cancers of the urinary tract. Because of these known toxicities, herbs containing this compound have been restricted or banned in some countries, but it is still available on the internet and in alternate formulations. By analyzing numerous samples from Taiwan and other countries in Asia and elsewhere, Ng et al. demonstrated the effects of aristolochic acid in hepatocellular carcinoma, a much more common tumor type. The authors showed that the use of this drug remains widespread in Asia and particularly in Taiwan, and that it appears to increase the risk of multiple different cancer types. http://stm.sciencemag.org/content/9/412/eaan6446 衛福部/中藥製劑中馬兜鈴酸成分之調查 本次所抽查的99件檢體其處方名及件數如表一，經高效液相層析法分析，結果只有1件 處方標示含有木防己的檢體檢出馬兜鈴酸I成分，檢測值為4.94 ppm（4.94 μg/g）， 推測應為藥材攙雜少量廣防己所造成，一般市售製劑之處方應使用粉防己、漢防己、 川木通、木香等不含馬兜鈴酸成分之藥材 https://imgur.com/PBiGjsh https://www.fda.gov.tw/TC/PublishHistoryB.aspx?pn=57 --

※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 101.13.180.26 ※ 文章網址: https://webptt.com/m.aspx?n=bbs/ChineseMed/M.1509875370.A.EE1.html